![Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-021-00289-7/MediaObjects/41523_2021_289_Fig1_HTML.png)
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer
![Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-021-01463-2/MediaObjects/13058_2021_1463_Fig1_HTML.png)
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text
![PDF] MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | Semantic Scholar PDF] MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c159668b9470c9a75ba2c701ff4a3403f305b644/2-Figure1-1.png)
PDF] MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | Semantic Scholar
![Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | SpringerLink Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12282-021-01295-0/MediaObjects/12282_2021_1295_Fig1_HTML.png)
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | SpringerLink
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f4de198d-b2f2-4e80-b658-ce30b4b9918a/gr1.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
![Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2020/08/Figures-Tables-EL.jpg)
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
![Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2020-0604/asset/images/medium/figure1.gif)
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology
![Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy | npj Breast Cancer Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-018-0094-2/MediaObjects/41523_2018_94_Fig4_HTML.png)
Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy | npj Breast Cancer
![Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-021-01463-2/MediaObjects/13058_2021_1463_Fig3_HTML.png)
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d1288ff9-0c7f-4332-b902-f99345f8a27e/figs1.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
![Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2020/08/Figure-3-Primary-endpoint-progression-free-surviva.jpg)
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
![Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials - Toi - 2021 - Cancer Science - Wiley Online Library Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials - Toi - 2021 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/4811dafa-4bf6-42a4-b62d-8704b4290b2e/cas14877-fig-0001-m.jpg)
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2− advanced breast cancer: MONARCH 2 & 3 trials - Toi - 2021 - Cancer Science - Wiley Online Library
![Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer](https://www.jcancer.org/v11/p7127/jcav11p7127g002.jpg)
Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
![Overall survival between matched MONARCH 1 and real-world chemotherapy... | Download Scientific Diagram Overall survival between matched MONARCH 1 and real-world chemotherapy... | Download Scientific Diagram](https://www.researchgate.net/publication/343624914/figure/fig1/AS:961370048720896@1606219889002/Overall-survival-between-matched-MONARCH-1-and-real-world-chemotherapy-cohort-p-value_Q640.jpg)
Overall survival between matched MONARCH 1 and real-world chemotherapy... | Download Scientific Diagram
![Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2020-0604/asset/images/medium/figure2.gif)
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology
![PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1b316b998a6f3d4685942edb98b16960acc9a40c/4-Figure2-1.png)
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar
![MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-018-0097-z/MediaObjects/41523_2018_97_Fig4_HTML.png)